Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

Roselie Achten; Daphne Bakker; Lieneke Ariens; Amanda Lans; Judith Thijs; Jorien van der Schaft; Joke de Boer; Deepak Balak; Marlies de Graaf; Chantal van Luijk; Marjolein de Bruin-Weller

doi:10.1016/j.jaip.2020.09.042

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

Roselie Achten
, Daphne Bakker
, Lieneke Ariens
, Amanda Lans
, Judith Thijs
, Jorien van der Schaft
, Joke de Boer
, Deepak Balak
, Marlies de Graaf
, Chantal van Luijk
, Marjolein de Bruin-Weller

Research output: Contribution to journal › Article › Academic › peer-review

22 Downloads (Pure)

Original language	English
Pages (from-to)	1389-1392.e2
Journal	The journal of allergy and clinical immunology. In practice
Volume	9
Issue number	3
Early online date	7 Oct 2020
DOIs	https://doi.org/10.1016/j.jaip.2020.09.042
Publication status	Published - Mar 2021

Access to Document

10.1016/j.jaip.2020.09.042

1-s2.0-S2213219820310916-mainFinal published version, 215 KBLicence: CC BY

Cite this

Achten, R., Bakker, D., Ariens, L., Lans, A., Thijs, J., van der Schaft, J., de Boer, J., Balak, D., de Graaf, M., van Luijk, C., & de Bruin-Weller, M. (2021). Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. The journal of allergy and clinical immunology. In practice, 9(3), 1389-1392.e2. https://doi.org/10.1016/j.jaip.2020.09.042

@article{ee29bdbc456643cd8e49c2d00fa4d4b2,

title = "Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis",

author = "Roselie Achten and Daphne Bakker and Lieneke Ariens and Amanda Lans and Judith Thijs and \{van der Schaft\}, Jorien and \{de Boer\}, Joke and Deepak Balak and \{de Graaf\}, Marlies and \{van Luijk\}, Chantal and \{de Bruin-Weller\}, Marjolein",

note = "Funding Information: Patients included in this manuscript participated in the BioDay registry sponsored by Sanofi Genzyme.Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie ; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. ",

year = "2021",

month = mar,

doi = "10.1016/j.jaip.2020.09.042",

language = "English",

volume = "9",

pages = "1389--1392.e2",

journal = "The journal of allergy and clinical immunology. In practice",

issn = "2213-2201",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "3",

}

Achten, R, Bakker, D, Ariens, L, Lans, A, Thijs, J, van der Schaft, J, de Boer, J, Balak, D, de Graaf, M, van Luijk, C & de Bruin-Weller, M 2021, 'Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis', The journal of allergy and clinical immunology. In practice, vol. 9, no. 3, pp. 1389-1392.e2. https://doi.org/10.1016/j.jaip.2020.09.042

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. / Achten, Roselie; Bakker, Daphne; Ariens, Lieneke et al.
In: The journal of allergy and clinical immunology. In practice, Vol. 9, No. 3, 03.2021, p. 1389-1392.e2.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

AU - Achten, Roselie

AU - Bakker, Daphne

AU - Ariens, Lieneke

AU - Lans, Amanda

AU - Thijs, Judith

AU - van der Schaft, Jorien

AU - de Boer, Joke

AU - Balak, Deepak

AU - de Graaf, Marlies

AU - van Luijk, Chantal

AU - de Bruin-Weller, Marjolein

N1 - Funding Information: Patients included in this manuscript participated in the BioDay registry sponsored by Sanofi Genzyme.Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie ; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2021/3

Y1 - 2021/3

UR - https://www.scopus.com/pages/publications/85093953013

U2 - 10.1016/j.jaip.2020.09.042

DO - 10.1016/j.jaip.2020.09.042

M3 - Article

C2 - 33038589

SN - 2213-2201

VL - 9

SP - 1389-1392.e2

JO - The journal of allergy and clinical immunology. In practice

JF - The journal of allergy and clinical immunology. In practice

IS - 3

ER -

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

Access to Document

Other files and links

Cite this